Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 : vimarsana.com

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

DUBLIN, April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio...

Related Keywords

Dublin , Ireland , United States , America , Theravance Biopharma , Rhonda Farnum , Italo Biaggioni , Horacio Kaufmann , Feliciab Axelrod , Rick Winningham , Theravance Biopharma Inc , Dysautonomia Center , Vanderbilt Autonomic Dysfunction Center , York University Grossman School Of Medicine , Prnewswire Theravance Biopharma Inc , Neurological Institute , Division Of Autonomic Disorders , Langone Health , National Institute Of Neurological Disorders , Movement Disorders Society , Kaufmann , Clinical Autonomic Research , New York University Grossman School , Pharmacology Director , Aine Miller , Chief Business Officer , Axelrod Professor , Autonomic Disorders , Pure Autonomic Failure , Natural History Study , Clinical Trial Readiness , Orphan Drug Designation , Multiple System Atrophy , Symptomatic Neurogenic Orthostatic Hypotension , Neurological Disorders ,